Regeneron Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Regeneron Pharmaceuticals, Inc.

Oct-28	Regeneron Reports Third Quarter 2025 Financial and Operating Results REGN GlobeNewswire
Oct-17	Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation REGN GlobeNewswire
Oct-15	Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers REGN GlobeNewswire
Oct-12	DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss REGN GlobeNewswire
Oct-08	Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation REGN GlobeNewswire
Sep-30	Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 REGN GlobeNewswire
Sep-26	Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol REGN GlobeNewswire
Sep-22	Dupixent (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion REGN GlobeNewswire
Sep-19	Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks REGN GlobeNewswire
Sep-17	Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD REGN GlobeNewswire
Sep-17	Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation REGN GlobeNewswire
Sep-09	Libtayo (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer REGN GlobeNewswire
Sep-08	Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies REGN GlobeNewswire
Sep-04	Regeneron Announces Updated Presentation Time for Upcoming Investor Conference REGN GlobeNewswire
Aug-26	Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis REGN GlobeNewswire
Aug-20	EYLEA HD (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension REGN GlobeNewswire
Aug-07	Regeneron Announces Investor Conference Presentations REGN GlobeNewswire
Aug-01	Regeneron Reports Second Quarter 2025 Financial and Operating Results REGN GlobeNewswire
Jul-24	Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation REGN GlobeNewswire
Jul-02	Lynozyfic (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma REGN GlobeNewswire
Jun-26	Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 REGN GlobeNewswire
Jun-24	Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization REGN GlobeNewswire
Jun-20	Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) REGN GlobeNewswire
Jun-15	Dupixent (dupilumab) Demonstrated Superiority Over Xolair (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial REGN GlobeNewswire
Jun-07	Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color REGN GlobeNewswire
Jun-02	Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist REGN GlobeNewswire
Jun-02	Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass REGN GlobeNewswire
May-31	Libtayo (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing REGN GlobeNewswire
May-30	Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials REGN GlobeNewswire
May-22	Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma REGN GlobeNewswire
May-19	Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness REGN GlobeNewswire
May-16	75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition REGN GlobeNewswire
May-15	Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments REGN GlobeNewswire
May-01	Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination REGN GlobeNewswire
May-01	Dupixent (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases REGN GlobeNewswire

Regeneron Pharmaceuticals, Inc.

Recent Articles by Regeneron Pharmaceuticals, Inc.

Upgrade your FINVIZ experience